tirzepatide cardiovascular outcomes trial results august 2025 and the 10‐year predicted risk of disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT‐1 - Hankosky Comparison of tirzepatide and dulaglutide

You might be a good candidate if you: Have a BMI of 30 or higher Have a BMI of 27 or higher with a weight-related health condition Tried diet and exercise without lasting success Want medical support for your weight loss goals We determine your tirzepatide dosage based on your health needs

Most experts recommend against tirzepatide use during breastfeeding until safety data becomes available

At microdose levels, the differences may be less pronounced because neither medication is fully activating its target receptors

Tirzepatide is dosed in milligrams, with available doses ranging from 2.5 mg to 15 mg administered weekly

The data supports its use

So for NAION, knowing that by taking this medication you are putting yourself at a slight increase of that happening, though again, the chances are extremely rare. While some studies have shown a possible concern for the development of NAION, Dr